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1.1
PHASE I/II STUDY OF FRACTIONATED RADIOIMMUNOTHERAPY 
(RIT) IN RELAPSED LOW GRADE NON-HODGKIN’S 
LYMPHOMA (NHL).
M. Bayne , M. Zivanovic , Y. Du , A. Tutt , G. Mead , P. Johnson ,
V . Lewington , T. Illidge 
CR UK Wessex Medical Oncology Unit, University of Southampton., 
Southampton, United Kingdom
RIT in “low grade” NHL produces high objective response rates with durable 
complete responses. The most impressive results, suggesting that there may be 
a radiation dose response for RIT, have been reported in clinical studies using 
high myeloablative dose RIT followed by peripheral blood stem cell transplant 
(PBSCT). The development of a human anti-mouse antibody response 
usually prevents more than one administration of RIT using the commercially 
available murine radioimmunoconjugates 131I tositumomab (BexxarTM) and 
90Y ibritumomab tiuxetan (ZevalinTM). Using a radioimmunoconjugate derived 
from the chimeric mAb rituximab, multiple or fractionated treatments are 
possible. Fractionation may enable higher cumulative doses of RIT to be 
delivered without the need for PBSCT. Using a dose escalation protocol 
this study tests the safety and efﬁ  cacy of fractionated RIT in relapsed CD20 
positive NHL using 2 fractions of 131I labelled rituximab preceded by an 
induction course of unlabelled rituximab. All 8 patients in the ﬁ  rst 2 dose 
cohorts have responded with acceptable toxicity and results from 12 patients 
will be available at the time of presentation. 
Sequential pharmacokinetic analyses have identiﬁ  ed wide variation in the 
effective half-life of 131I-rituximab not only between patients but also within 
the same patient over the course of the treatment protocol. The mean effective 
half-life of 131I rituximab increases from 43 hours prior to induction rituximab 
to 106 hours prior to the second fraction of 131I-rituximab. An anti-rituximab 
idiotype monoclonal antibody (mAb) has been generated to enable serial 
analysis of serum rituximab concentrations. This tool has aided analysis of 
the impact of induction unlabelled rituximab, the pre-dose and fractionation 
on the clearance and biodistribution of the radioimmunoconjugate. Our results 
indicate a need to individualise the scheduling of RIT in order to improve the 
biodistribution of radioimmunoconjugate and maximize the therapeutic ratio.   
1.2
A PHASE I/II TRIAL OF ANTIBODY DIRECTED ENZYME 
PRODRUG THERAPY (ADEPT) WITH MFECP1 AND ZD2767P 
A Mayer , R Francis , SK Sharma , C Sully , S Parker , B Tolner , N Grifﬁ  n 
, M Germain , P Beckett , B Tolner , G Boxer , A Green , KA Chester , RHJ 
Begent 
Department of Oncology, Royal Free Campus, University College London, 
London, United Kingdom
Antibody-directed enzyme prodrug therapy (ADEPT) is based on administration
of an anti-tumour antibody enzyme complex followed by prodrug, which is
converted to active drug at the tumour site. We report interim results of the Phase
I study of single administration of ADEPT with MFECP1, a fusion protein of
carboxypeptidase G2 (CPG2) and the anti-CEA scFv antibody MFE-23, and the
bis-iodo phenol mustard prodrug ZD2767P. MFECP1 was developed to fulﬁ  l the
design criteria of tumour localisation with rapid clearance.
Twenty-eight patients (15 male, 13 female; median age 64 years; range 35-78
years) with unresectable, locally recurrent or metastatic histologically proven
colorectal or other CEA expressing cancer (serum CEA <1000ug/l) were
included, 27 have completed the study. Patients #1-23 received 5000U/m2
MFECP1 and patients #24-28 3000U/m2 MFECP1, ZD2767P was escalated in
two-fold increments from 12.42mg/m2 x3 to 1075mg/m2 x3. 
MFECP1 cleared rapidly via the liver, the alpha half life was 0.5h and 0.44h and
the beta half life 4.6h and 1.96h for 5000U/m2 MFECP1 and 3000U/m2 MFECP1,
respectively. Based on SPECT imaging CPG2 in tumour was estimated to be
0.18U/g, 0.07U/g and 0.02U/g after 4h, 20h and 40h, respectively. Localisation
was conﬁ  rmed by immunohistochemistry up to 17 h after administration of
MFECP1, prodrug activation by comet assay. Dose limiting toxicity was seen
for the combination of 5000U/m2 MFECP1 and 1075mg/m2 x3 and 3000U/
m2 MFECP1 and 537.5mg/m2. The combination of 3000U/m2 MFECP1 and
268.8mg/m2 was found to be safe and well tolerated. 0/27 patients had detectable
HAMA, 10/27 detectable HACA.  9/27 patients achieved SD with 1 patient
showing a 10% reduction of tumour diameter, 16 PD and 2 were not evaluable. 
In conclusion, DLT and MTD for the combination of MFECP1 and ZD2767P
were determined in the current phase I trial, efﬁ  cacy will be tested after giving
repeated treatment. MFECP1 cleared rapidly, localised in tumour and has less
immunogenic potential than previous antibody enzyme conjugates.  
1.3
PHASE II RANDOMISED DISCONTINUATION STUDY OF 
BAY  43-9006 IN PATIENTS WITH ADVANCED MELANOMA
T Ahmad 1, R Marais 2, L Pyle 1, M James 1, B Schwartz 3, M Gore 1, 
T Eisen 1
1 Royal Marsden Hospital, London, United Kingdom, 2 Institute of 
Cancer Research, London, United Kingdom, 3 Bayer Pharmaceutical 
Corporation, West Haven, United States
Background Approximately 70% of melanomas have an activating mutation 
in BRAF, leading to elevated kinase activity and cellular proliferation. BAY 
43-9006 is a potent RAF kinase inhibitor that retards the growth of human 
melanoma xenografts. This phase II study aims to determine the clinical 
beneﬁ  t and toxicity of BAY 43-9006 in advanced melanoma and to correlate 
these ﬁ  ndings with BRAF status of the patients and their tumours.
Methods Patients with stage IV refractory melanoma were treated with BAY 
43-9006 400mg BD orally for 12 weeks after baseline imaging and biopsy of 
tumour and normal skin. At the 12 week reassessment, patients with objective 
tumour responses continued BAY 43-9006 until disease progression or 
unacceptable toxicity. Patients with stable disease were randomised in a 
double-blind manner between BAY 43-9006 and placebo and followed for 
on-going response. In the event of disease progression in this cohort, the 
code was broken and those receiving placebo were rechallenged with BAY 
43-9006. Tumour responses were evaluated by CT/MRI at 12 weeks and 
every 6 weeks thereafter and tumour biopsies taken at 0, 4, 12 weeks for 
sequencing BRAF and identiﬁ  cation of downstream activity of RAF kinase.
Results Twenty patients were enrolled between October 2002 and April 
2003, the median age was 52 years.At week 12, 1 partial response and 3 
stable disease were seen. Fifteen patients had progressive disease before or 
at 12 weeks. Grade 3 skin toxicity was observed in 5 patients and 2 patients 
developed hypertension requiring intervention.There was no haematological 
toxicity and all toxicity was reversible. Laboratory analysis of tumours to 
determine BRAF status will be presented.
Conclusion  BAY 43-9006 has very modest activity as a single agent. 
Preliminary data from combination studies are promising and studies are 
ongoing.The drug is well-tolerated and the determination of BRAF status 
in patients may allow correlation with clinical behaviour of  tumours and 
efﬁ  cacy of BAY 43-9006.
1.4
INITIAL PHASE 1 STUDY OF XR5944, A NOVEL DNA AND RNA 
TARGETING AGENT 
EM Rankin , D Bissett , M Nicolson , H Thomas , J Steiner , M Cooper , 
G Mellows , G Allen , D Norris , J Waterfall 
1 United Kingdom, Division of Cancer Medicine, University of 
Dundee, Dundee, 2 United Kingdom, Grampian Universities NHS 
Trust, Aberdeen, 3 United Kingdom, St Lukes Cancer Centre, 
Guildford, 4 United Kingdom, Xenova Ltd, Slough, 5 United Kingdom, 
Millennium Pharmaceuticals, Cambridge
Background: XR5944 (MLN944) is a novel DNA/RNA targeting agent with
a mechanism of action distinct from that of currently available cytotoxic
chemotherapeutic agents.  XR5944 binds to the major groove of DNA
and inhibits RNA synthesis with an EC50 = 3 nM. Because of XR5944’s
unique mechanism of action and activity across several human tumor cell
lines and xenograft models, we have initiated a phase I clinical trial of this
compound in patients with advanced, treatment-refractory solid tumors.
XR5944 is given as a single 30 minute intravenous infusion repeated once
every 21-28 days. The starting dose was 3.6 mg/m2, which is a NOAEL
(no observable adverse effect level) in the most sensitive species and is
just below one-tenth of the MTD. Preclinical toxicologic evaluation of
XR5944 suggests dose-limiting toxicities of reversible myelosuppression
and gastrointestinal epithelial damage. Dose escalation follows a modiﬁ  ed
Fibonnaci search scheme, with 2 patients at each dose level until CTC ≥
grade 2 drug-related toxicity is seen. After the occurrence of such toxicity
cohorts of 3-6 patients will be evaluated at that dose level.  To establish
the dose for Phase 2 studies, 9-15 patients will be treated at the MTD.
To date 12 patients have been enrolled, 2 patients each at initial dose levels
of 3.6, 7.2, 14 and 24 mg/m2 and one at 36 mg/m2.  At the highest level
one patient experienced grade III mucositis and one grade IV neutropenia
and so 3 patients have been treated at 30 mg/m2 so far without any dose
limiting toxicity.  The pharmacokinetics of XR5944 are linear over the dose
range of 3.6 to 24 mg/m2, with mean (SD) CL = 29.6 (6.4) L/hour/m2, Vss
= 937 (382) L/m2, and t1/2 = 61.8 (13.4) hours. The average AUC0-t and Cmax
at a dose of 24 mg/m2 are 1060 ng-hr/mL and 1090 ng/mL, respectively.
Patient entry continues and updated results will be reported.
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PRECLINICAL EVALUATION OF AW464 (NSC 706704), A NOVEL 
THIOREDOXIN INHIBITOR
A Mukherjee 1, TD Bradshaw 1, AD Westwell 1, MFG Stevens 1,
J Carmichael 2, SG Martin 1
1 University of Nottingham, Nottingham, United Kingdom, 2 Astra 
Zeneca, Cheshire, United Kingdom
AW464 (NSC 706704) is a novel benzothiazole substituted quinol 
compound active in colon, renal and certain breast cancer cell lines. 
NCI COMPARE analysis indicates thioredoxin/ thioredoxin reductase 
signalling as a possible target. Thioredoxin has been shown to be 
upregulated under hypoxia and through its activity on HIF1α also 
induces VEGF. This study investigated the potential anti-angiogenic 
effects, both direct and indirect (via altered growth factor production), 
and altered hypoxic cytotoxicity of AW464. In vitro experiments 
(growth curves, MTS, clonogenic survival assays, ELISA’s and RT-
PCR) were performed on HT29, SW480 and SW620 colorectal and 
MCF7 breast cancer cell lines under normoxic and hypoxic conditions. 
Results were compared against those obtained with normal cell lines, 
viz. MRCV foetal lung ﬁ  broblasts, normal human dermal ﬁ  broblasts 
(NHDF) and neonatal human epidermal keratinocytes (NHEK). Anti-
angiogenic effects were studied using large, human umbilical vein and 
microvessel, human mammary microvessel endothelial cells (HUVEC 
and HUMMEC, respectively). Results indicate that AW464 exerted 
anti-proliferative effects on tumour cell lines and endothelial cells 
with an IC50 of ∼0.5µM. Of the normal cell lines, only NHDF and 
MRCV ﬁ  broblasts were resistant to the IC50 dose. Proliferating, but 
not quiescent endothelial cells were sensitive to the drug, indicating 
anti-angiogenic activity. Hypoxia (1% O2 for 48 hours) decreased 
proliferation and clonogenic survival of colorectal cells at lower drug 
concentrations (<IC50). At these doses, under hypoxic conditions, there 
was a greater inhibition of VEGF production in HT29 cells. In contrast, 
bFGF levels were unaffected, suggesting possible involvement of 
HIF1α. AW464 may be a promising chemotherapeutic drug for colon 
cancer that may possess enhanced hypoxic potency and also direct and 
indirect anti-angiogenic activity.
1.6
IMPROVING BREAST CANCER TREATMENT USING NOVEL 
POLY(ADP-RIBOSE) POLYMERASE-1 (PARP-1) INHIBITORS
SJ Veuger , BW Durkacz 
United States, Northern Institute for Cancer Research, Newcastle upon 
Tyne
NFkB is a stress-inducible transcription complex that induces genes
which control proliferation responses and suppress apoptotic cascades.
Constitutive activation of NFkB is common in malignant tumours,
including breast. PARP-1 is activated as an immediate cellular response
to DNA damage. Recent reports have shown reduced NFkB-dependent
gene activation in PARP-1 -/- cells suggesting a role for PARP-1 as a co-
activator of NFkB. 
The effect of IR ± a potent PARP-1 inhibitor (AG14361) on NFkB activity
was assessed in breast cancer cell lines which express constitutively
activated (MDA-MB-231) or inducible (T47D) NFkB. Once activated,
NFkB translocates from the cytosol to the nucleus where it binds to
speciﬁ  c NFkB response elements. Following 20 Gy IR, translocation to
the nucleus was seen 1h post-IR in the T47D cells (Western blotting) and
this was unaffected by 0.4 µM AG14361. Moreover, translocation was
also observed in PARP-1 -/-  mouse embryonic ﬁ  broblasts (MEFs). 
The effect of IR ± AG14361 on binding to a NFkB consensus sequence
was assessed using an EMSA-based assay. Maximal activation of NFkB
by 20 Gy IR was seen after 2h in the MDA-MB-231 cell line.  Exposure
to AG14361 for 3 h had no effect on constitutive NFkB activity.  However,
pre-incubation with 0.1 µM AG14361 for 1 h followed by 2h post-IR (20
Gy) incubation at 37°C completely inhibited the IR activation of NFkB
in this cell line. 
The ability of AG14361 to potentiate IR in these cell lines was
investigated.  AG14361 sensitised exponentially growing MDA-MB-231
and T47D cells to IR 1.3 and 1.2 -fold, respectively.   
These studies demonstrate an involvement of PARP-1 in the activation
of NFkB independent of the signalling cascades through which NFkB is
induced and suggest that strategies utilising PARP-1 inhibitors to block
NFkB activity in breast tumours should complement existing cancer
therapies
1.7
THE ROLE OF P53 IN CHEMOTHERAPY-INDUCED AND DEATH 
RECEPTOR-MEDIATED APOPTOSIS IN COLON CANCER
U McDermott , L Galligan , DB Longley , PG Johnston 
Queen’s University Belfast, Belfast, United Kingdom
The tumour necrosis factor family of death receptors are expressed 
on a variety of human cancers and include Fas/CD95 and the TRAIL 
receptors DR4 and DR5. Upon binding of their cognate ligands (FasL 
and TRAIL) these death receptors induce apoptosis, representing 
a potential target for novel therapeutic agents. A variety of chemo-
therapeutic agents have been shown to cause up-regulation of the Fas 
receptor in cancer cell lines. Furthermore, while DR4/DR5 are expressed 
in both normal and tumour cells, rTRAIL selectively induces apoptosis 
in tumours. There is increasing interest in the therapeutic potential of 
agonistic anti-Fas antibodies and recombinant TRAIL (rTRAIL) and 
how they might increase the cytotoxicity of chemo-therapeutic agents. 
We examined the therapeutic potential of targeting the Fas and TRAIL 
pathways in combination with therapeutic agents used in the treatment 
of colorectal cancer. We have demonstrated by MTT cell viability assay, 
ﬂ  ow cytometry analysis and PARP cleavage assay a highly signiﬁ  cant 
synergy between the agonistic anti-Fas antibody CH-11 or rTRAIL in 
the p53 wild-type HCT116 colon cancer cell line co-treated with the 
chemotherapeutic agents 5-FU, CPT-11 and oxaliplatin. We also observed 
activation of procaspase 8 when CH-11 or rTRAIL were added after 
treatment with each of these drugs. In the case of CH-11 treatment, 
the increased cytotoxicity is associated with induction of the Fas/CD95 
receptor. We used the isogenic p53 null HCT116 colon cancer cell line 
to determine whether these synergistic interactions were p53-dependent. 
No synergy was observed between CH-11 and 5-FU or oxaliplatin in the 
p53 null cells. However, signiﬁ  cant synergy was observed between CPT-
11 and CH-11 in these cells. Interestingly, this did not correlate with Fas 
induction in response to CPT-11 in the p53 null cell line. Initial results 
suggest that the synergy between rTRAIL and each of the cytotoxic drugs 
may not be p53-dependent. These results begin to characterise the role of 
p53 in regulating death receptor-mediated apoptosis in colon cancer cells 
following treatment with chemotherapy.
1.8
CELECOXIB TREATMENT LEADS TO DECREASED 
CYCLOOXYGENASE-2 (COX-2) EXPRESSION IN A XENOGRAFT 
MODEL OF BREAST CANCER 
NLP Barnes 1, F Warnberg 1, D White 2, E Anderson 2, NJ Bundred 1
1 South Manchester University Hospital and The Christie Hospital NHS 
Trust, Manchester, United Kingdom, 2 The Christie Hospital NHS Trust, 
Manchester, United Kingdom
COX-2 is an inducible enzyme active in the pathway of conversion from
arachidonic acid to prostaglandins. Its over-expression is associated with
increased early recurrence and decreased survival in breast cancer. COX-2
inhibition has been associated with increased apoptosis and anti-angiogenesis,
but no clear surrogate marker has been identiﬁ  ed. Our aim was to assess the
effect of COX-2 inhibition on tumour growth and COX-2 protein expression
in a xenograft model.
Either MCF7/HER-18 or MDAMB231 breast cancer cells were injected into
the ﬂ  anks of nude mice and allowed to form tumours. The mice were then
randomised to receive either 0.15% Celecoxib (a COX-2 inhibitor) or control
chow. Tumour volumes were measured, and when they reached 1cm3 the
experiment was ended and tumours were harvested. COX-2 expression was
determined immunohistochemically on formalin-ﬁ  xed,  parafﬁ  n-embedded
tumour sections.
Cell line
Median control 
Growth (mm3) [IQR]
Median COX-2 
positive cells (%) 
[IQR]
MCF7/ HER-
18 
Control (n=70)
                        
100 [35-178] 65 [60-77]
Treated (n=62)  39 [4-156]* 23 [1-60]**
MDAMB231    
                      
Control (n=19)  96 [51-284] 27 [12-32]
Treated (n=21)  30 [0-53]***  9 [4-18]****
[IQR=Interquartile range] *p=0.029 **p=0.0001 ***p=0.0002 ****p=0.046
(Mann Whitney U-Test)
COX-2 is highly expressed in MCF7/HER-18 cells and was seen to be
contained within vesicles in MDAMB231 cells.
Administration of Celecoxib signiﬁ   cantly decreased both tumour growth
and COX-2 protein expression. Therefore, COX-2 expression itself could
potentially be used as a surrogate marker of the effects of COX-2 inhibitors. 
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